NO157783C - Fremgangsmaate for fremstilling av et heparinfragment covalent bundet til antitrombin iii, og et mellomprodukt for fremstilling av heparinfragmentforbindelsen. - Google Patents

Fremgangsmaate for fremstilling av et heparinfragment covalent bundet til antitrombin iii, og et mellomprodukt for fremstilling av heparinfragmentforbindelsen.

Info

Publication number
NO157783C
NO157783C NO832092A NO832092A NO157783C NO 157783 C NO157783 C NO 157783C NO 832092 A NO832092 A NO 832092A NO 832092 A NO832092 A NO 832092A NO 157783 C NO157783 C NO 157783C
Authority
NO
Norway
Prior art keywords
preparation
heparin fragment
procedure
intermediate product
compound
Prior art date
Application number
NO832092A
Other languages
English (en)
Norwegian (no)
Other versions
NO157783B (no
NO832092L (no
Inventor
Desire J Collen
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Publication of NO832092L publication Critical patent/NO832092L/no
Publication of NO157783B publication Critical patent/NO157783B/no
Publication of NO157783C publication Critical patent/NO157783C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
NO832092A 1982-06-10 1983-06-09 Fremgangsmaate for fremstilling av et heparinfragment covalent bundet til antitrombin iii, og et mellomprodukt for fremstilling av heparinfragmentforbindelsen. NO157783C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8203611 1982-06-10

Publications (3)

Publication Number Publication Date
NO832092L NO832092L (no) 1983-12-12
NO157783B NO157783B (no) 1988-02-08
NO157783C true NO157783C (no) 1988-05-18

Family

ID=20347038

Family Applications (1)

Application Number Title Priority Date Filing Date
NO832092A NO157783C (no) 1982-06-10 1983-06-09 Fremgangsmaate for fremstilling av et heparinfragment covalent bundet til antitrombin iii, og et mellomprodukt for fremstilling av heparinfragmentforbindelsen.

Country Status (8)

Country Link
US (1) US4623718A (de)
EP (1) EP0098814B1 (de)
JP (1) JPS5925802A (de)
AT (1) ATE22899T1 (de)
CA (1) CA1205011A (de)
DE (2) DE98814T1 (de)
DK (1) DK258283A (de)
NO (1) NO157783C (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422518A1 (de) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
EP0337327A1 (de) * 1988-04-09 1989-10-18 Bioiberica, S.A. Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
US5252557A (en) * 1988-07-25 1993-10-12 Kiyoshi Kita Administration method of antithrombin
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US7498130B2 (en) * 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
EP1663299A4 (de) * 2003-08-12 2009-09-16 Hamilton Civic Hospitals Res Verfahren zur prävention von neurologischen ereignissen
CN103743837B (zh) * 2013-12-24 2015-01-21 山东泰邦生物制品有限公司 人抗凝血酶ⅲ肝素结合比例检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12779T1 (de) * 1980-09-30 1985-05-15 Bayer Ag Verfahren zur herstellung eines antithrombinheparin-komplexes sowie diesen komplex enthaltende pharmazeutische mischungen.

Also Published As

Publication number Publication date
NO157783B (no) 1988-02-08
NO832092L (no) 1983-12-12
JPS5925802A (ja) 1984-02-09
CA1205011A (en) 1986-05-27
DE3366933D1 (en) 1986-11-20
DE98814T1 (de) 1984-06-20
DK258283D0 (da) 1983-06-07
ATE22899T1 (de) 1986-11-15
EP0098814B1 (de) 1986-10-15
DK258283A (da) 1983-12-11
EP0098814A1 (de) 1984-01-18
US4623718A (en) 1986-11-18

Similar Documents

Publication Publication Date Title
PT76394A (fr) Procede de preparation de nouveaux conjugues associant par liaison covalente une enzyme et un anticorps
DE3851844D1 (de) Kugelfestes kompositerzeugnis.
CY1405A (en) Novel antihistamines, process for their preparation and pharmaceutical compositions containing them
NO176306C (no) Fremgangsmåte for fremstilling av stjerneformede konjugater
ES8402290A1 (es) Procedimiento para la preparacion de nuevos 6,11-dihidrodibenzo (b,e)-tiepin-11-n-alcohilnorescopin-eteres cuaternarios.
IT7919700A0 (it) Laminati di vetro e resina sintetica e procedimento per laloro produzione.
NO882966D0 (no) Fremgangsmaate for fremstilling av metall-andre fasekompositter og derved fremstilt produkt.
ATE94395T1 (de) Verwendung von spezifischen monosacchariden zur herstellung eines arzneimittels zur verhinderung von metastasen maligner tumore.
FI892390A (fi) Process och anordning foer maskintvaettning av linnetyger medelst en partikelformig produkt och anordning foer utnyttjande av processen.
NO157783C (no) Fremgangsmaate for fremstilling av et heparinfragment covalent bundet til antitrombin iii, og et mellomprodukt for fremstilling av heparinfragmentforbindelsen.
IL71366A0 (en) Immunoglobulin conjugates,their production and pharmaceutical compositions containing them
DE3484315D1 (de) Messvorrichtung zur herstellung von nach mass hergestellten artikeln.
IL64292A (en) D-homoandrostane-17alpha-carboxylic acids,derivatives thereof and 17alpha-spiroethers,their manufacture and pharmaceutical compositions containing them
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DK118582A (da) Kemokinesiner og kemotainer samt fremgangsmaade til fremstilling deraf
PT73706B (fr) Procede de preparation de nouvelles glycoproteines extraites deklebsiella pneumoniae
NO880179D0 (no) Polymerkomplekser, fremgangsmaate for fremstilling av disse, og farmasoeytiske midler inneholdende disse.
FI844732A0 (fi) Produkt, foerfarande och anordning foer att kontrollera sinandet av ett hoelje.
ES2006079A6 (es) Un procedimiento de preparacion de polimeros yodados.
ZA875176B (en) Immunotozins,process for their preparation and pharmaceutical compositions in which they are present
IT8622424A0 (it) Procedimento per la produzione di resina poliestere ad alto peso molecolare.
IL59295A0 (en) Dehydropeptide compounds,their production and pharmaceutical compositions containing them
FI884418A0 (fi) Hjaertskyddande aemne och ett terapeutiskt aemne foer ischemiska sjukdomar omfattande n-innehaollande heterocykliska foereningar, och ett foerfarande foer framstaellning av dessa foereningar.
IT8123541A0 (it) Composti citostatici, procedimento per la loro preparazione e composizioni farmaceutiche contenti gli stessi.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas